Table 2.
CAR T-cell therapy in DLBCL patients failing CD19-directed treatment
| Patients (N = 14) | |
|---|---|
| CD19 expression on lymphoma cells after loncastuximab tesirine therapy, n (%) | |
| Positive | 10 (71) |
| Not checked | 4 (29) |
| Median interval between loncastuximab tesirine and CAR T-cell therapy (range), d | 120 (22-600) |
| Additional therapy between loncastuximab tesirine and CAR T-cell therapy, n (%) | |
| Yes* | 6 (43) |
| No | 8 (57) |
| Disease status before CAR T-cell therapy, n (%) | |
| Refractory disease | 5 (36) |
| Progressive disease | 8 (57) |
| Partial remission | 1 (7) |
| Flu/Cy lymphodepletion, n (%) | 14 (100) |
| Type of CAR T-cell therapy, n (%) | |
| Axicabtagene ciloleucel | 5 (36) |
| Tisagenlecleucel | 2 (14) |
| Investigational targeting CD19† | 4 (29) |
| JCAR017 | 3 (21) |
| Best response to CAR T-cell therapy, n (%) | |
| Complete response | 6 (43) |
| Partial response | 1 (7) |
| Refractory disease | 7 (50) |
| CRS grade, n (%) | |
| None | 6 (43) |
| 1 | 3 (21) |
| 2 | 4 (29) |
| 3 | 1 (7) |
| ICANS grade, n (%) | |
| None | 8 (57) |
| 1 | 4 (29) |
| 2 | 1 (7) |
| 3 | 0 (0) |
| 4 | 1 (7) |
CRS, cytokine release syndrome; Flu/Cy, lymphodepletion with fludarabine/cyclophosphamide.
*
Additional therapy between loncastuximab tesirine and CAR T-cell therapy included radiation alone (n = 3), radiation, ifosphamide/vinblastine/etoposide (n = 1), radiation; rituximab/methotrexate (n = 1), lenalidomide, anti-CD47 antibody, ibrutinib (n = 1).
†
One patient each received a CD19/CD22-directed CAR, and a CD19/CD20-directed CAR. Neither patient responded to CAR treatment.